These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 6137135)

  • 1. Experimental pharmacology of Alzheimer disease.
    Greenwald BS; Davis KL
    Adv Neurol; 1983; 38():87-102. PubMed ID: 6137135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An update on the neurochemistry of Alzheimer disease.
    Davies P
    Adv Neurol; 1983; 38():75-86. PubMed ID: 6137134
    [No Abstract]   [Full Text] [Related]  

  • 3. m2 muscarinic acetylcholine receptor-immunoreactive neurons are not reduced within the nucleus basalis in Alzheimer's disease: relationship with cholinergic and galaninergic perikarya.
    Mufson EJ; Jaffar S; Levey AI
    J Comp Neurol; 1998 Mar; 392(3):313-29. PubMed ID: 9511920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development.
    Terry AV; Buccafusco JJ
    J Pharmacol Exp Ther; 2003 Sep; 306(3):821-7. PubMed ID: 12805474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disturbances in neurotransmission processes in aging and age-related diseases.
    Ossowska K
    Pol J Pharmacol; 1993; 45(2):109-31. PubMed ID: 8401765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of physostigmine and lecithin on memory in Alzheimer disease.
    Peters BH; Levin HS
    Ann Neurol; 1979 Sep; 6(3):219-21. PubMed ID: 534419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic brain cytochrome oxidase inhibition selectively alters hippocampal cholinergic innervation and impairs memory: prevention by ladostigil.
    Luques L; Shoham S; Weinstock M
    Exp Neurol; 2007 Aug; 206(2):209-19. PubMed ID: 17580085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neurotransmitters in Alzheimer's disease].
    Manzano-Palomo S; De la Morena-Vicente MA; Barquero MS
    Rev Neurol; 2006 Mar 16-31; 42(6):350-3. PubMed ID: 16575771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of novel arecoline thiazolidinones as muscarinic receptor 1 agonist in Alzheimer's dementia models.
    Chandra JN; Malviya M; Sadashiva CT; Subhash MN; Rangappa KS
    Neurochem Int; 2008 Feb; 52(3):376-83. PubMed ID: 17719699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apoptotic signals within the basal forebrain cholinergic neurons in Alzheimer's disease.
    Wu CK; Thal L; Pizzo D; Hansen L; Masliah E; Geula C
    Exp Neurol; 2005 Oct; 195(2):484-96. PubMed ID: 16085017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The involvement of cholinergic and noradrenergic systems in behavioral recovery following oxotremorine treatment to chronically stressed rats.
    Srikumar BN; Raju TR; Shankaranarayana Rao BS
    Neuroscience; 2006 Dec; 143(3):679-88. PubMed ID: 17008021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Tacrine].
    Dávila C; Viteri C; de Castro P
    Rev Med Univ Navarra; 1997; 41(1):58-64. PubMed ID: 9527715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impaired coupling of muscarinic M1 receptors to G-proteins in the neocortex is associated with severity of dementia in Alzheimer's disease.
    Tsang SW; Lai MK; Kirvell S; Francis PT; Esiri MM; Hope T; Chen CP; Wong PT
    Neurobiol Aging; 2006 Sep; 27(9):1216-23. PubMed ID: 16129514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholinergic markers in Alzheimer disease and the autoregulation of acetylcholine release.
    Quirion R
    J Psychiatry Neurosci; 1993 Nov; 18(5):226-34. PubMed ID: 8297921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease.
    Pákáski M; Kálmán J
    Neurochem Int; 2008 Nov; 53(5):103-11. PubMed ID: 18602955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurochemical approaches to the treatment of senile dementia.
    Growdon JH; Corkin S
    Proc Annu Meet Am Psychopathol Assoc; 1980; 69():281-96. PubMed ID: 7413654
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacologic challenges in Alzheimer disease and normal controls: cognitive modeling in humans.
    Sunderland T; Molchan SE; Little JT; Bahro M; Putnam KT; Weingartner H
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 4():S23-6. PubMed ID: 9339269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of transmitter release from the locust forewing stretch receptor neuron by GABAergic interneurons activated via muscarinic receptors.
    Judge S; Leitch B
    J Neurobiol; 1999 Sep; 40(3):420-31. PubMed ID: 10440741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Further evidence for the cholinergic hypothesis of aging and dementia from the canine model of aging.
    Araujo JA; Studzinski CM; Milgram NW
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Mar; 29(3):411-22. PubMed ID: 15795050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of cholinergic systems by manganese.
    Finkelstein Y; Milatovic D; Aschner M
    Neurotoxicology; 2007 Sep; 28(5):1003-14. PubMed ID: 17920128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.